구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Isatuximab SAR650984 |
Overview Company | Sanofi |
Overview Modality | ANTIBODY |
Overview Target | Plasma Cell Myeloma |
Overview Indication | Immune System Disorder |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells |
MoA Biomarker | biomarker and therapeutic target for multiple myeloma due to its high expression on cancerous cells in compar |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells.. Bispecific antibody recruiters (BARs) are an innovative class of immunotherapeutics that redirect endogenous antibodies to tumor cells. BARs comprise a tumor-binding and an antibody-binding module, enabling endogenous antibodies to opsonize tumor cells and i… |
Clinical Safety signal | CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells.. Bispecific antibody recruiters (BARs) are an innovative class of immunotherapeutics that redirect endogenous antibodies to tumor cells. BARs comprise a tumor-binding and an antibody-binding module, enabling endogenous antibodies to opsonize tumor cells and i… |
Clinical Selected reported efficacy | ORR 55.6% |
Clinical Reported ORR | 55.6% |
Clinical Result source | ClinicalTrials.gov NCT03769181 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT03769181 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Isatuximab SAR650984 |
Overview Company | Sanofi |
Overview Modality | ANTIBODY |
Overview Target | Plasma Cell Myeloma |
Overview Indication | Immune System Disorder |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells |
MoA Biomarker | biomarker and therapeutic target for multiple myeloma due to its high expression on cancerous cells in compar |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells.. Bispecific antibody recruiters (BARs) are an innovative class of immunotherapeutics that redirect endogenous antibodies to tumor cells. BARs comprise a tumor-binding and an antibody-binding module, enabling endogenous antibodies to opsonize tumor cells and i… |
Clinical Safety signal | CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells.. Bispecific antibody recruiters (BARs) are an innovative class of immunotherapeutics that redirect endogenous antibodies to tumor cells. BARs comprise a tumor-binding and an antibody-binding module, enabling endogenous antibodies to opsonize tumor cells and i… |
Clinical Selected reported efficacy | ORR 55.6% |
Clinical Reported ORR | 55.6% |
Clinical Result source | ClinicalTrials.gov NCT03769181 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT03769181 |
추천 비교
추천 비교